At a hackathon over the weekend, students worked with real brain data to create new tools for brain-machine systems. The post ...
Boehringer Ingelheim has reported encouraging Phase II trial results for apecotrep (BI 764198), a potential first-in-class oral TRPC6 inhibitor being developed for primary focal segmental ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results